Cambridge Epigenetix – Improving health through measurement of the epigenome

 

Innovative technology and services for DNA methylation analysis

Our vision is a world where epigenetics helps to tackle the most pressing issues of our time and improves health and wellness for everyone. Here at Cambridge Epigenetix, we believe great things happen when people work together. The biggest leaps in human understanding come from collaboration: when the right specialisms, interests and ambitions combine, the benefits are exponential.

Through combining novel technology with scientific excellence, we are the partner of choice for the discovery of epigenetic biomarkers and development of clinical diagnostic assays. Our experienced team comprises world-leading specialists in biomarker development with core expertise in the identification of robust epigenetic signatures from liquid biopsy samples and cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) as well as solid tissue biopsy samples in oncology and other diseases. 

The company is a University of Cambridge spin-out headquartered in Cambridge, UK, and is financed by leading venture capital companies including GV (Google Ventures), Sequoia Capital, Syncona, and New Science Ventures.

 


About Us
 
TrueMethyl analysis

Our Products

TrueMethyl
Seq

Sufficient for 24 oxidative bisulfite (oxBS) reactions and 24 bisulfite (BS)-only reactions

Learn more

TrueMethyl
Array

Sufficient for 96 oxidative bisulfite (oxBS) reactions and 96 bisulfite (BS)-only reactions

Learn more

TrueMethyl
Whole-Genome

For the preparation of 48 TrueMethyl® converted and indexed DNA libraries for Illumina® sequencing

Learn more
Newsletter

To get the latest news delivered to your inbox, signup below.